Edition:
United States

Obalon Therapeutics Inc (OBLN.OQ)

OBLN.OQ on NASDAQ Stock Exchange Global Market

1.91USD
20 Jul 2018
Change (% chg)

$0.05 (+2.69%)
Prev Close
$1.86
Open
$1.86
Day's High
$1.98
Day's Low
$1.86
Volume
12,488
Avg. Vol
25,374
52-wk High
$10.35
52-wk Low
$1.85

Chart for

About

Obalon Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in... (more)

Overall

Beta: --
Market Cap(Mil.): $32.68
Shares Outstanding(Mil.): 17.57
Dividend: --
Yield (%): --

Financials

  OBLN.OQ Industry Sector
P/E (TTM): -- 43.98 33.34
EPS (TTM): -2.32 -- --
ROI: -79.60 14.54 13.18
ROE: -96.07 17.68 15.09

BRIEF-Obalon Reports Q1 Loss Per Share $0.71

* Q1 EARNINGS PER SHARE VIEW $-0.50 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

May 10 2018

BRIEF-Obalon Therapeutics Q4 Loss Per Share $0.60

* OBALON ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 05 2018

BRIEF-Obalon Therapeutics Says Audit Committee's Investigation Into Purported Whistleblower Complaint Concluded Allegations Are Meritless

* OBALON THERAPEUTICS - AUDIT COMMITTEE COMPLETED INVESTIGATION INTO PURPORTED WHISTLEBLOWER COMPLAINT; CONCLUDED ALLEGATIONS ARE MERITLESS

Feb 20 2018

Obalon cancels offering after allegation on accounting practices

Jan 23 Obalon Therapeutics Inc said on Tuesday it canceled a stock offering after the medical device maker, known for its swallowable balloons that aid in weight loss, was accused of improper accounting practices.

Jan 23 2018

Earnings vs. Estimates